Loading...

Brilliant Violet 605™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_BV605_013112
C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 605™.
  • RM4-5_BV605_013112
    C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 605™.
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
100547 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100548 50 µg 219€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  2. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  3. Metzger R, et al. 2019. Front Oncol. 1.070138889. PubMed
  4. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  5. Schädlich IS, et al. 2022. iScience. 25:104470. PubMed
  6. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  7. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  8. Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed
  9. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  10. Israelow B, et al. 2020. bioRxiv. . PubMed
  11. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  12. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  13. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  14. Webb LMC, et al. 2021. Aging Cell. 20:e13295. PubMed
  15. Sano T, et al. 2021. Cell Reports. 36:109608. PubMed
  16. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  17. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  18. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
  19. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  20. Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed
  21. Wei SC, et al. 2019. Immunity. 50:1084. PubMed
  22. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  23. Ward E, Fu H, Marelli-Berg F 2017. Methods Mol Biol. 10.1007/978-1-4939-6931-9_15. PubMed
  24. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  25. Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
  26. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  27. Marangoni F, et al. 2021. Cell. . PubMed
  28. Latif AL, et al. 2021. Nat Commun. 0.667361111. PubMed
  29. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  30. Beom JY, et al. 2019. J Nat Prod. 82:2078. PubMed
  31. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  32. Muppidi J, et al. 2015. J Exp Med. 212: 2213 - 2222. PubMed
  33. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  34. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  35. Hartwig T et al. 2018. Cell reports. 25(13):3564-3572 . PubMed
  36. Colliou N, et al. 2018. Gut Microbes. 9:279. PubMed
  37. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  38. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  39. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  40. Doron I, et al. 2021. Cell. 184(4):1017-1031.e14. PubMed
  41. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  42. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  43. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  44. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
  45. Lewis EL, et al. 2021. Front Immunol. 12:741518. PubMed
  46. Jyh Liang Hor, William R. Heath, Scott N. Mueller 2017. Sci Rep. 7:41091. PubMed
  47. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  48. Wu B, et al. 2020. Int J Biol Sci. 16:1526. PubMed
  49. Camell CD, et al. 2020. Cell Metabolism. 30(6):1024-1039.e6.. PubMed
  50. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  51. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  52. Sheldon RD, et al. 2021. Nat Protoc. 16:4494. PubMed
  53. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  54. Bruder J, et al. 2017. Mol Ther Methods Clin Dev. 10.1016/j.omtm.2017.08.003. PubMed
  55. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  56. Klein JC, et al. 2017. Nat Commun. 8:14600. PubMed
  57. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  58. Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed
  59. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  60. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  61. McAndrews KM, et al. 2021. J Biol Chem. 296:100523. PubMed
  62. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  63. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  64. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  65. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  66. Wang S, et al. 2022. J Inflamm Res. 14:7107. PubMed
  67. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  68. Collins N, et al. 2020. Cell. 178(5):1088-1101.e15.. PubMed
  69. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  70. Silva DA, et al. 2019. Nature. 565:186. PubMed
  71. Ravussin A, et al. 2018. Cell Rep. 24:1085. PubMed
  72. Mangas KM, et al. 2020. Infect Immun. 88:. PubMed
  73. Wei Y, et al. 2021. Endocrinology. 162(8):. PubMed
  74. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  75. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  76. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  77. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  78. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  79. Dhayade S, et al. 2020. Nutrients. 12:. PubMed
  80. Truckenbrod EN, et al. 2021. Elife. 10:. PubMed
  81. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  82. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  83. Baker GJ, et al. 2020. Cell Syst. 0.647222222. PubMed
  84. Lee Y, et al. 2018. Antimicrob Agents Chemother. 62:00:00. PubMed
  85. Sharma M, et al. 2019. Immunometabolism. 1. PubMed
  86. Graham JB, et al. 2017. Curr Protoc Mouse Biol. 7:221. PubMed
  87. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
  88. Li X, et al. 2018. Cell Host Microbe. 24:847. PubMed
  89. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  90. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  91. Spath S, et al. 2022. iScience. 25:104998. PubMed
  92. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  93. Ge Y, et al. 2020. Mucosal Immunol. 13:34. PubMed
  94. Young A, et al. 2017. Cancer Res. 77:4684. PubMed
  95. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  96. Nascimento DC, et al. 2021. Immunity. :. PubMed
  97. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
RRID
AB_11125962 (BioLegend Cat. No. 100547)
AB_2563054 (BioLegend Cat. No. 100548)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 2    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account